Details

Autor(en) / Beteiligte

• Daniel, Eleni
• Newell-Price, John D C

Titel

Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome

Ist Teil von

• European journal of endocrinology, 2015-06, Vol.172 (6), p.R263

Ort / Verlag

England

Erscheinungsjahr

2015

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Steroidogenesis enzyme inhibitors are the mainstay of medical therapy in Cushing's syndrome (CS). Ketoconazole (KTZ) and metyrapone are the most commonly used agents. Although there is considerable experience of their use in individual specialist centres, these drugs have not been rigorously tested in prospective clinical trials. Clinicians face uncertainties and concerns with respect to the safety profile of these agents, and best means to monitor effect. We review steroidogenesis inhibitors in the management of CS, including older agents (KTZ, metyrapone, etomidate and mitotane) and those currently under development (LCI699, non-racemic KTZ), and offer a practical approach for their use in clinical practice.